Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy

Executive Summary

The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.

You may also be interested in...

Bristol’s Oncology Strategy: Stay In The Lead On Immunotherapy

At the recent ASCO meeting, Bristol’s immunotherapies had a very high profile, paving the way for further development of the company’s PD-1/CTLA-4 combination and development of checkpoint inhibitors in new tumor types.

ASCO Preview: Elotuzumab’s ‘Double Whammy’ Mechanism Hits Hard In Myeloma

Lead investigator for Bristol/AbbVie’s Phase III ELOQUENT trial of elotuzumab in myeloma says PFS curves are reminiscent of PD-1 inhibitors, expects overall survival benefit to be evident soon.

Big Market, Broad Plan: Bristol Shares Vision For Opdivo In Lung Cancer

Releasing positive results for Opdivo in the Phase II CheckMate-063 study in highly refractory squamous-type NSCLC, Bristol explains its big tent development program, which tests the PD-1 inhibitor with immunotherapies as well as targeted drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts